| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.3M | +11.2% | +94.9% |
| SG&A Expense | $1.7M | -0.2% | +28.1% |
| Net Income | -$3.9M | -6.8% | -68.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $1.8M | +9.7% | -41.3% |
| Current Assets | $6.0M | -29.1% | -42.7% |
| Total Assets | $6.4M | -27.9% | -43.6% |
| Current Liabilities | $5.8M | +32.9% | +65.9% |
| Total Liabilities | $7.6M | +20.1% | +28.4% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.5M | — | — |
| Investing Cash Flow | $7.0M | — | — |
| Financing Cash Flow | -$277K | — | — |
| -$1.2M |
| -147.6% |
| -122.3% |